Management of MPN beyond JAK2

Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.

The acquired somatic JAK2-V617F mutation is present in >80% of patients with myeloproliferative neoplasms (MPNs). Stat3 plays a role in hematopoietic homeostasis and might influence the JAK2-V617F-driven MPN phenotype. We crossed our transgenic SclCre;V617F mice with a conditional Stat3 knockout strain and performed bone marrow transplantations into lethally irradiated recipient mice. The delet...

CYT387, A NOVEL JAK2 INHIBITOR, INDUCES HEMATOLOGIC RESPONSES AND NORMALIZES INFLAMMATORY CYTOKINES IN MURINE MYELOPROLIFERATIVE NEOPLASMS Running Title: Novel JAK2 Inhibitor for MPN

Oregon Health & Sciences University Knight Cancer Institute, Portland, OR 97239, USA Oregon Health & Sciences University School of Nursing, School of Medicine, Department of Radiation Medicine, Portland, OR 97239, USA 3 Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria Oregon Health & Science University Department of Pathology, P...

Advancing the STATus of MPN pathogenesis.

In this issue of Blood, Yan et al and Walz et al exploit mouse genetics to investigate the contribution of signal transducer and activator of transcription 5 (STAT5) to the abnormal in vivo growth of hematopoietic cells expressing JAK2(V617F) or BCR-ABL. Eliminating STAT5 expression had dramatic effects in both contexts, and this new work and other recent studies support the therapeutic potenti...

Closing the gap: genetic landscape of MPN.

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

BACKGROUND Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are at increased risk for thrombosis/thromboembolism and major bleeding. Due to the morbidity and mortality of these events, antiplatelet and/or anticoagulant agents are commonly employed as primary and/or secondary prophylaxis...